Pharmacological targeting of striatal indirect pathway neurons improves subthalamic nucleus dysfunction and reduces repetitive behaviors in C58 mice

Behav Brain Res. 2020 Aug 5:391:112708. doi: 10.1016/j.bbr.2020.112708. Epub 2020 May 24.

Abstract

Repetitive behaviors (e.g., stereotypic movements, compulsions, rituals) are common features of a number of neurodevelopmental disorders. Clinical and animal model studies point to the importance of cortical-basal ganglia circuitry in the mediation of repetitive behaviors. In the current study, we tested whether a drug cocktail (dopamine D2 receptor antagonist + adenosine A2A receptor agonist + glutamate mGlu5 positive allosteric modulator) designed to activate the indirect basal ganglia pathway would reduce repetitive behavior in C58 mice after both acute and sub-chronic administration. In addition, we hypothesized that sub-chronic administration (i.e. 7 days of twice-daily injections) would increase the functional activation of the subthalamic nucleus (STN), a key node of the indirect pathway. Functional activation of STN was indexed by dendritic spine density, analysis of GABA, glutamate, and synaptic plasticity genes, and cytochrome oxidase activity. The drug cocktail used significantly reduced repetitive motor behavior in C58 mice after one night as well as seven nights of twice-nightly injections. These effects did not reflect generalized motor behavior suppression as non-repetitive motor behaviors such as grooming, digging and eating were not reduced relative to vehicle. Sub-chronic drug treatment targeting striatopallidal neurons resulted in significant changes in the STN, including a four-fold increase in brain-derived neurotrophic factor (BDNF) mRNA expression as well as a significant increase in dendritic spine density. The present findings are consistent with, and extend, our prior work linking decreased functioning of the indirect basal ganglia pathway to expression of repetitive motor behavior in C58 mice and suggest novel therapeutic targets.

Keywords: Autism spectrum disorder; Basal ganglia; Indirect pathway; Neurodevelopmental disorders; Obsessive compulsive disorder; Repetitive behavior; Subthalamic nucleus.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Animals
  • Autism Spectrum Disorder / drug therapy
  • Autism Spectrum Disorder / physiopathology
  • Basal Ganglia / physiology
  • Behavior, Animal / drug effects
  • Benzamides / pharmacology
  • Compulsive Behavior / drug therapy
  • Corpus Striatum / physiology
  • Disease Models, Animal
  • Indoles / pharmacology
  • Male
  • Mice
  • Mice, Inbred Strains
  • Neural Pathways / physiology
  • Neurons / metabolism
  • Phenethylamines / pharmacology
  • Piperidines / pharmacology
  • Pyrazoles / pharmacology
  • Stereotyped Behavior / drug effects*
  • Stereotyped Behavior / physiology
  • Subthalamic Nucleus / drug effects*
  • Subthalamic Nucleus / metabolism

Substances

  • 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
  • Benzamides
  • Indoles
  • Phenethylamines
  • Piperidines
  • Pyrazoles
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole
  • Adenosine